Biomimetic Innovations Limited – Trademark Portfolio
Entity Type: 99
Biomimetic Innovations Limited holds 3 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 42 (Computer & Scientific) — 3 filings in this category. The portfolio also extends into Class 10 (Medical Apparatus) across 4 Nice Classification classes. Currently, 1 trademark is registered and 2 are pending. Notable registered marks include S OSSTIC. The owner is based in Shannon Co. Clare.
Unit 4D
Shannon Co. Clare V14RW92 , IE
Showing of trademarks Trademarks
Trademark Classifications
Biomimetic Innovations Limited's trademark portfolio spans 4 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Scientific and technological services; industrial analysis and research services
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Frequently Asked Questions
How many trademarks does Biomimetic Innovations Limited have?
Biomimetic Innovations Limited has 3 U.S. trademarks filed with the USPTO. Of these, 1 registered, 2 pending.
What trademark classes does Biomimetic Innovations Limited file in?
Biomimetic Innovations Limited files trademarks across 4 Nice Classification classes. The most active classes are Class 42 (Computer & Scientific), Class 10 (Medical Apparatus), Class 5 (Pharmaceuticals), Class 40 (Treatment & Processing). Class 42 covers scientific and technological services; industrial analysis and research services.
What are Biomimetic Innovations Limited's most well-known trademarks?
Biomimetic Innovations Limited's registered trademark portfolio includes well-known marks such as S OSSTIC. These are among 1 currently registered trademark in the portfolio.
What is Biomimetic Innovations Limited's trademark registration success rate?
Biomimetic Innovations Limited has a 100% trademark registration rate, with 1 out of 1 resolved applications resulting in successful registration. Currently, 2 applications are pending review.